Targeted Cell Therapies Overview

  • Founded
  • 2006
  • Status
  • Private
  • Employees
  • 4
  • Latest Deal Type
  • Angel
  • Investors
  • 2

Targeted Cell Therapies General Information


Provider of a technology platform in oral delivery sector. The company offers delivery technology platform to address needs in the oral delivery of large molecule drugs for a broad range of disease conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Healthcare Technology Systems
Other Industries
Drug Delivery
Primary Office
  • 60 Prescott Street
  • Worcester, MA 01605
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Targeted Cell Therapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 31-Oct-2013 00000 Completed Startup
1. Seed Round 06-Dec-2007 00000 00000 Completed Startup
To view Targeted Cell Therapies’s complete valuation and funding history, request access »

Targeted Cell Therapies Executive Team (3)

Name Title Board Seat Contact Info
Edward Ginns Ph.D Co-Founder, Interim CEO & President
Siddarth Rathi MD Chief Strategy Officer
You’re viewing 2 of 3 executive team members. Get the full list »

Targeted Cell Therapies Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Targeted Cell Therapies Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Kin-Joe Sham Angel (individual) Minority 000 0000 000000 0
Seth Ginns Angel (individual) Minority 000 0000 000000 0
To view Targeted Cell Therapies’s complete investors history, request access »